IDEAYA Biosciences (IDYA) vs Perrigo (PRGO)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Perrigo (PRGO) has outperformed IDEAYA Biosciences (IDYA) over the past year, gaining 26.1% versus a loss of 24.8%. Over five years, IDYA leads with a +7.3% price change compared with -57.8% for PRGO. IDEAYA Biosciences is the larger company by market cap ($2.47 billion vs $2.21 billion), about 1.1 times the size.
Perrigo pays a dividend yielding 7.28%, while IDEAYA Biosciences does not currently pay one. Perrigo converts more of its revenue into profit, with a net margin of -33.5% versus -52.0%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | IDYA | PRGO |
|---|---|---|
| Share price | $25.56 | $15.94 |
| Market cap | $2.47B | $2.21B |
| 1-day change | -2.33% | -0.62% |
| YTD return | -26.06% | +14.51% |
| 1-year return | -24.80% | +26.11% |
| 5-year return | +7.35% | -57.81% |
| Forward P/E | — | 6.94 |
| EPS (TTM) | $-4.50 | $-12.47 |
| Dividend yield | 0.00% | 7.28% |
| Annual dividend | $0.00 | $1.16 |
| Revenue (latest FY) | $218.71M | $4.25B |
| Revenue growth (YoY) | +3024.43% | -2.75% |
| Net income (latest FY) | $-113.70M | $-1.43B |
| Gross margin | — | 35.14% |
| Operating margin | -72.84% | -26.39% |
| Net margin | -51.99% | -33.51% |
| 52-week high | $42.68 | $17.07 |
| 52-week low | $25.46 | $9.23 |
| Distance from 52-week high | -40.11% | -6.62% |
| Analyst consensus | strong_buy | buy |
| Avg. price target upside | +98.32% | +12.92% |
| Average volume | 933.58K | 2.54M |
| Shares outstanding | 96.69M | 138.80M |
| Employees | 145 | 8,100 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- PRGO has outperformed IDYA by 50.9 percentage points over the past year.
- Perrigo offers a meaningfully higher dividend yield (7.28% vs 0.00%).
- Perrigo is more profitable, keeping -33.5 cents of every revenue dollar as net income versus -52.0 cents for IDEAYA Biosciences.
- IDEAYA Biosciences grew revenue faster in its latest fiscal year (+3024.43% vs -2.75%).
About IDEAYA Biosciences
IDYA stock →IDEAYA Biosciences, Inc., a precision medicine oncology company, develops targeted therapeutics for patient populations selected using molecular diagnostics in the United States. The company offers Darovasertib, an oral, potent, and selective protein kinase, C (PKC) inhibitor for the treatment of uveal melanoma, ocular cancer, and is being evaluated in multiple clinical trials as monotherapy and in combination with crizotinib for metastatic, neoadjuvant, and adjuvant settings.
Health Care · Biotechnology: Pharmaceutical Preparations · 145 employees
About Perrigo
PRGO stock →Perrigo Company plc provides over-the-counter health and wellness solutions in the United States, Europe, and internationally. The company operates through Consumer Self-Care Americas and Consumer Self-Care International segments.
Health Care · Biotechnology: Pharmaceutical Preparations · 8,100 employees
IDYA vs PRGO FAQ
Which is bigger, IDEAYA Biosciences or Perrigo?
IDEAYA Biosciences (IDYA) is larger, with a market capitalization of $2.47B compared with $2.21B for Perrigo (PRGO).
Which stock has performed better over the past year, IDYA or PRGO?
PRGO returned +26.11% over the past 12 months, compared with -24.80% for IDYA (price return, excluding dividends). Past performance does not predict future results.
Which pays a higher dividend, IDEAYA Biosciences or Perrigo?
Perrigo pays a dividend yielding 7.28%, while IDEAYA Biosciences does not currently pay a regular dividend.
Are IDEAYA Biosciences and Perrigo in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.